Biomea Fusion
BMEA
Market cap $379M

10.48 USD

+0.39

3.87%

At close Oct 4, 4:00 PM EDT

After hours

10.47

-0.01

0.1%

1 day

3.87%

5 days

6.07%

1 month

48.02%

3 months

118.33%

6 months

-16.23%

Year to date

-28.56%

1 year

-17.09%

5 years

-43.66%

About: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Employees: 112

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

507% more call options, than puts

Call options by funds: $9.21M | Put options by funds: $1.52M

18% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 28

2% more funds holding

Funds holding: 103 [Q1] → 105 (+2) [Q2]

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

23.41% less ownership

Funds ownership: 88.56% [Q1] → 65.15% (-23.41%) [Q2]

78% less capital invested

Capital invested by funds: $473M [Q1] → $105M (-$367M) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

14%

downside

Avg. target

$28

167%

upside

High target

$54

415%

upside

8 analyst ratings

7 positive

88%

1 neutral

13%

0 negative

0%

Scotiabank George Farmer 12% 1-year accuracy 2 / 17 met price target	291%upside $41	Sector Outperform Maintained	27 Sept 2024
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 87 / 281 met price target	282%upside $40	Buy Maintained	27 Sept 2024
Barclays Peter Lawson 28% 1-year accuracy 8 / 29 met price target	14%downside $9	Equal-Weight Maintained	27 Sept 2024
Truist Securities Srikripa Devarakonda 50% 1-year accuracy 12 / 24 met price target	415%upside $54	Buy Upgraded	27 Sept 2024
Rodman & Renshaw Tony Butler 67% 1-year accuracy 2 / 3 met price target	72%upside $18	Buy Upgraded	26 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 51 articles about BMEA published over the past 30 days

Shareholders that lost money on Biomea Fusion, Inc.(BMEA) should contact Levi & Korsinsky about Securities Fraud Investigation - BMEA

NEW YORK, NY / ACCESSWIRE / October 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Shareholders that lost money on Biomea Fusion, Inc.(BMEA) should contact Levi & Korsinsky about Securities Fraud Investigation - BMEA

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - BMEA

NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - BMEA

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions

LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

$The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions$

An Investigation Has Commenced on Behalf of Biomea Fusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BMEA Losses

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

An Investigation Has Commenced on Behalf of Biomea Fusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BMEA Losses

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - BMEA

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - BMEA

Biomea Fusion, Inc. Is Being Looked Into For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion, Inc. Is Being Looked Into For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

See News Rankings

Charts implemented using Lightweight Charts™